上市公司独立董事提名人声明与承诺 提名人 汉威科技集团股份有限公司董事会 现就提名 刘之斐 为 汉威科技集团 股份有限公司第 七 届董事会独立董 事候选人发表公开声明。被提名人已书面同意作为 汉威科技集 团 股份有限公司第 七 届董事会独立董事候选人（参见该独立 董事候选人声明）。 本次提名是在充分了解被提名人职业、学历、职称、详细的 工作经历、全部兼职、有无重大失信等不良记录等情况后作出的， 本提名人认为被提名人符合相关法律、行政法规、部门规章、规 范性文件和深圳证券交易所业务规则对独立董事候选人任职资格 及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过 汉威科技集团 股份有限公司第 六 届董事会提名委员会或者独立董事专门会议资格审查，提名人 与被提名人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 ☑ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百七十 八条等规定不得担任公司董事的情形。 ☑ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办 法》和深圳证券交易所业务规则规定的独立董事任职资格 和条件。 ☑ 是 □ 否 四、被提名人符合公司章程规定的独立董 ...

证券代码：300007 证券简称：汉威科技 公告编号：2026-007 汉威科技集团股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （1）现场会议时间：2026 年 02 月 02 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 02 月 02 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2026 年 02 月 02 日 9:15 至 15:00 的 任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 01 月 27 日 7、出席对象： （1）截至股权登记日下午收市时，在中国证券登记结算有限责任公司深 圳分公司登记在册的公司全体股东均有权出席股东会，并可以以书面形式（附 件二：授权委托书）委托代理人出席会议和参加表决，该股东代理人可不必是 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董 ...

证券代码：300007 证券简称：汉威科技 公告编号：2026-003 汉威科技集团股份有限公司 第六届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次会议通知于 2026 年 1 月 12 日以邮件或通讯方式送达。 2、本次会议于 2026 年 1 月 16 日在公司会议室以现场结合通讯的方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 4、本次会议由董事长任红军先生主持，公司副总经理、董事会秘书肖锋先 生列席了会议。 5、本次董事会的召集、召开和表决程序符合《中华人民共和国公司法》及 《公司章程》的有关规定，表决所形成的决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司董事会换届选举暨提名第七届董事会非独立董事候 选人的议案》 鉴于公司第六届董事会任期即将届满，公司根据《公司法》及《公司章程》 等有关规定进行董事会换届选举。经公司董事会提名委员会资格审核，公司董事 会同意提名任红军先生、李志刚先生、尚中锋先生、杨昌再先生、肖锋先生为第 七届董事会非独立董事 ...

Core Viewpoint - Hanwei Technology's stock price has shown fluctuations, with a recent decline of 2.00% and a year-to-date increase of 8.62%, indicating mixed market sentiment towards the company [1]. Financial Performance - For the period from January to September 2025, Hanwei Technology achieved a revenue of 1.702 billion yuan, representing a year-on-year growth of 8.44%. The net profit attributable to shareholders was 84.843 million yuan, reflecting a growth of 6.33% compared to the previous year [2]. - Cumulatively, since its A-share listing, Hanwei Technology has distributed a total of 239 million yuan in dividends, with 9.481 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 79,400, up by 6.87%. The average number of circulating shares per person decreased by 6.43% to 3,566 shares [2]. - The stock's trading activity showed a net outflow of 96.6541 million yuan from major funds, with significant buying and selling activity from large orders [1]. Institutional Holdings - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Penghua Carbon Neutral Theme Mixed A and an increase by Hong Kong Central Clearing Limited. New entrants include several funds such as E Fund National Robot Industry ETF and Huashang Runfeng Mixed A [4].

证券代码：300007 证券简称：汉威科技 公告编号：2026-002 汉威科技集团股份有限公司 关于完成经营范围工商变更登记、《公司章程》备案并换发营业 执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 汉威科技集团股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召 开第六届董事会第二十五次会议、于 2025 年 11 月 18 日召开 2025 年第二次临时 股东大会，审议通过了《关于变更经营范围及修订<公司章程>的议案》。具体内 容详见公司于 2025 年 10 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于变更经营范围及修订<公司章程>的公告》（公告编号：2025-054）。 二、进展情况 近日，公司已完成经营范围工商变更登记、《公司章程》备案手续，并取得 了河南省市场监督管理局换发的《营业执照》，具体信息如下： 名称：汉威科技集团股份有限公司 经营范围：许可项目：建设工程施工（除核电站建设经营、民用机场建设）； 建筑智能化系统设计；建设工程设计；特种设备检验检测；测绘服务（依法 ...

Core Insights - The brain-computer interface (BCI) industry in China is experiencing significant advancements, with clinical results emerging for high-level paraplegics and substantial funding rounds, including a recent 2 billion yuan investment in a non-invasive unicorn company, Strong Brain Technology, marking the second-largest funding record globally in this field [1][2] - The industry is poised for rapid commercialization, driven by technological breakthroughs, capital influx, and supportive policies, as it transitions from cutting-edge technology to practical applications in daily life [1][5] Technological Breakthroughs - Recent advancements in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegics to control smart wheelchairs and robotic dogs [2][3] - Companies like JieTi Medical and Chip Intelligence have made significant progress, with JieTi completing trials for its invasive BCI system and Chip Intelligence's semi-invasive product achieving human implantation [2][3] - The first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology has shown promising results, allowing an 8-year paraplegic patient to achieve thought control just five days post-surgery [2][3] Policy and Capital Support - The BCI sector benefits from comprehensive policy support, including its designation as one of the six future industries in the 14th Five-Year Plan, which elevates it to a national strategic priority [5][6] - Recent initiatives by the Sichuan provincial medical insurance bureau have established pricing for 82 neuro-related medical services, including BCI applications, facilitating clinical adoption [5][6] - The establishment of industry standards by the National Medical Products Administration is expected to lower costs and risks associated with technology development and clinical application [6] Industry Collaboration and Investment - Companies like Baiyang Pharmaceutical are actively collaborating with academic institutions to explore the integration of BCI with artificial intelligence, aiming for innovative clinical solutions [7] - Other listed companies are also engaging in the BCI space through material supply and equipment development, indicating a strong interest from institutional investors [7] Future Development and Challenges - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [8] - Potential constraints include the pace of chip design and production, as well as the need for ethical regulations regarding personal brain data [8] - Despite these challenges, the domestic BCI industry holds significant advantages, including strong policy support, a vast clinical resource base, and a comprehensive supply chain [8] Investment Opportunities - The BCI sector presents a dual investment opportunity in both medical and technological domains, with short-term focus on disease treatment and long-term potential for enhancing human capabilities through integration with AI and robotics [9] - The industry is positioned to cultivate leading global BCI companies, fostering a capital-innovation synergy between primary and secondary markets [9]

Core Viewpoint - Hanwei Technology (300007) has made breakthroughs in the research and development of non-invasive flexible brain-machine interface materials and flexible neural electrode materials, although these technologies are still in the early stages and commercial application remains uncertain [1] Group 1 - The company has focused on flexible micro-nano sensor technology in recent years [1] - Key technological advancements include complex brain information collaborative monitoring and implantable flexible neural electrode materials [1] - The company collaborates with medical institutions and university research teams for R&D [1]

Core Viewpoint - The company has confirmed that its MEMS sensor packaging and testing production line has reached the intended operational status, and the products from this project can be utilized in various applications, including potentially providing "electronic noses" for embodied intelligent robots [1]. Group 1 - The fundraising project for the MEMS sensor packaging and testing line includes various products such as MEMS gas sensors and MEMS pressure sensors [1]. - The products from the MEMS sensor production line are applicable in multiple downstream sectors [1].

Core Viewpoint - The company, Hanwei Technology, does not currently engage in the production of quantum sensors or applications in quantum technology [2] Group 1 - Investors inquired about the company's involvement in quantum sensors on an investor interaction platform [2] - Hanwei Technology confirmed that it does not have products related to quantum technology at this time [2]

Group 1 - The core point of the article is that the company, Hanwei Technology, has successfully completed the construction and commenced operations of the first phase of its subsidiary Nengda's production line expansion, which has a reserved capacity of 500,000 pieces per year and aims to complete certification by the end of 2025 [2][3] Group 2 - The expansion of the production line is a significant step for the company, indicating growth and increased production capabilities in the near future [2] - The company has actively engaged with investors, providing updates on the progress of its projects through interactive platforms [2] - The completion of the first phase of the production line is expected to enhance the company's operational efficiency and market competitiveness [2]